For Q1 FY2026 (ended March 31, 2026), Arbutus Biopharma reported revenue of $179.1 million, a significant increase of over 10,000% year-over-year. Net income was $169.7 million, compared to a loss in the prior year, and diluted EPS was $0.87. Operating income was $168.9 million, and the company had no long-term debt. Cash stood at $23.7 million, and equity was $260.2 million.
•Revenue surged to $179.1M from $1.8M in Q1 FY2025.
•Net income of $169.7M vs. a loss of $24.5M a year ago.
•Diluted EPS of $0.87, up from $0.10.
•No long-term debt; equity of $260.2M.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. Formerly known as Tekmira Pharmaceuticals Corporation, the company rebranded as Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
What does Arbutus Biopharma Corporation (ABUS) do?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for infectious diseases, specifically chronic Hepatitis B virus (HBV). Its pipeline includes Imdusiran, a subcutaneously-delivered RNAi therapeutic product candidate currently in Phase 2a clinical trials, which aims to suppress all HBV antigens, including HBsAg expression. Additionally, the company is developing AB-101, an oral PD-L1 inhibitor in Phase 1a/1b clinical trials, designed to reawaken patients' HBV-specific immune response by inhibiting PD-L1. Arbutus also has a licensing agreement with Alnylam Pharmaceuticals to develop and commercialize products using LNP delivery technology.
Where is Arbutus Biopharma Corporation (ABUS) listed and in which currency?
Arbutus Biopharma Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ABUS. Its shares are traded in United States Dollars (USD), as the company is based in the United States. The exchange is a major U.S. stock exchange, providing liquidity and visibility for the company's stock.
What sector and industry does Arbutus Biopharma Corporation (ABUS) belong to?
Arbutus Biopharma Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on research and development of novel therapeutics for infectious diseases, particularly chronic Hepatitis B virus. Biotechnology companies like Arbutus typically engage in drug discovery, preclinical and clinical development, and may seek regulatory approval for their product candidates.
Where is Arbutus Biopharma Corporation (ABUS) headquartered and what is its history?
Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania, United States. The company was originally incorporated in 2005 under the name Tekmira Pharmaceuticals Corporation. It rebranded as Arbutus Biopharma Corporation in July 2015. The company's focus has been on developing therapies for infectious diseases, with a primary emphasis on chronic Hepatitis B virus. Its location in the United States allows it to operate within the U.S. regulatory and healthcare environment.
What is the business model of Arbutus Biopharma Corporation (ABUS) and how does it generate revenue?
As a clinical-stage biopharmaceutical company, Arbutus Biopharma Corporation does not yet have approved products on the market, so it does not generate revenue from product sales. Instead, its business model involves advancing its pipeline of therapeutic candidates through clinical trials with the goal of obtaining regulatory approval and eventually commercializing them. The company may also generate revenue through licensing agreements, such as its agreement with Alnylam Pharmaceuticals to develop and commercialize products using LNP delivery technology. Additionally, Arbutus may seek partnerships or collaborations to fund research and development activities.